<DOC>
	<DOCNO>NCT00352443</DOCNO>
	<brief_summary>RATIONALE : Lapatinib everolimus may stop growth cancer cell block enzymes need cell growth . Everolimus may also stop growth cancer cell block blood flow cancer . Giving lapatinib together everolimus may kill cancer cell . PURPOSE : This phase I trial study side effect best dose lapatinib everolimus treat patient advance solid tumor non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>S0528 Lapatinib Everolimus Treating Patients With Advanced Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Estimate maximum tolerate dose ( MTD ) lapatinib everolimus patient advance solid tumor non-Hodgkin 's lymphoma . ( Part I ) - Investigate pharmacokinetics everolimus lapatinib ( give alone combination ) MTD determine Part I . ( Part II ) - Investigate effect everolimus lapatinib ( give alone combination ) serum level vascular endothelial growth factor ( VEGF ) , basic fibroblast growth factor ( bFGF ) , matrix metalloproteinase ( MMP ) -2 MMP-9 , interleukin-6 ( IL-6 ) , tumor necrosis factor alpha ( TNF-α ) . ( Part II ) OUTLINE : This multicenter , dose-escalation study follow randomize study . Initial patient enrol study treat part I . After maximum tolerate dose ( MTD ) determine part I , subsequent patient enrol treated part II . - Part I : Patients receive oral everolimus oral lapatinib daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos everolimus lapatinib MTD determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Part II : Patients randomize 1 2 treatment arm . Everolimus lapatinib administer MTD determine part I . - Arm I : Patients receive oral everolimus daily day 1-28 . Patients also receive oral lapatinib daily day 8-28 first course day 1-28 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . - Arm II : Patients receive oral lapatinib daily day 1-28 . Patients also receive oral everolimus daily day 8-28 first course day 1-28 subsequent course . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients part II undergo blood collection periodically correlative biomarker pharmacokinetic study . After finish treatment , patient follow periodically 28 day . PROJECTED ACCRUAL : A total 48 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm advanced solid tumor nonHodgkin 's lymphoma curative option exist Measurable nonmeasurable disease Patients brain metastasis require corticosteroids anticonvulsant must stable decrease dose corticosteroid seizure free 30 day prior study entry Patients know brain metastasis must brain irradiation ( whole brain gamma knife ) No untreated ( nonirradiated ) brain metastasis PATIENT CHARACTERISTICS : Zubrod performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ SGOT SGPT ≤ 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Bilirubin normal Creatinine normal OR creatinine clearance &gt; 60 mL/min Cardiac ejection fraction normal echocardiogram MUGA Able swallow enteral medication No feed tube No intractable nausea vomit No gastrointestinal ( GI ) tract disease result inability take oral medication No current active hepatic biliary disease exception Gilbert 's syndrome asymptomatic gallstone No malabsorption syndrome No requirement IV alimentation No uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) No history allergic reaction attribute compound similar chemical biologic composition lapatinib everolimus , include quinazoline compound , gefitinib erlotinib , rapamycins , sirolimus temsirolimus No known HIV positivity No concurrent uncontrolled illness , include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Myocardial infarction cerebrovascular accident within past 3 month Uncontrolled diarrhea Psychiatric illness social situation would preclude compliance study requirement Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Willing undergo pharmacokinetic ( PK ) sample blood collection PK correlative study ( patient enrol part II ) PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior lapatinib everolimus No prior surgical procedure affect absorption More 14 day since prior major surgery , chemotherapy ( 42 day nitrosoureas mitomycin C ) , radiotherapy More 28 day since prior investigational agent At least 7 day since prior concurrent CYP3A4 inhibitor At least 14 day since prior concurrent CYP3A4 inducer At least 14 day since prior concurrent herbal dietary supplement No concurrent chemotherapy , hormone therapy , radiotherapy , immunotherapy , live vaccine anticancer therapy Concurrent luteinizing hormonereleasing hormone agonist allow Concurrent bisphosphonates epoetin alfa analogue allow No concurrent gastric H2 blocker ( e.g. , cimetidine , ranitidine , nizatidine , famotidine ) proton pump inhibitor ( e.g. , omeprazole , esomeprazole , rabeprazole , pantoprazole , lansoprazole ) Antacids allow provide administer within 1 hour lapatinib No concurrent glucocorticoid immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
</DOC>